In recent years, the quietly emerged Lao Big Bear version of Sotorasib, an affordable alternative to this targeted therapy for refractory KRAS G12C mu···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 146
The Laotian Bear version of Sotorasib, as the first generic version of the world's first approved KRAS G12C inhibitor original drug, is produced b···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 118
In today's context of increasing attention to targeted anti-tumor drugs, the Laos Dabear version of Encorafenib, with its compliant production bac···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 124
As one of the first generic versions of the original drug Encorafenib, the Lao Big Bear version of Encorafenib, with proven equivalence and significan···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 126
The generic version of Encorafenib launched by Lao Big Bear Pharmaceutical provides a more accessible option for patients worldwide who need BRAF inhi···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 132
The Laos Daxiong version of Axitinib strictly adheres to international generic drug production standards, providing clinicians and patients with a val···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 123
Against the backdrop of increasing global demand for anticancer drugs, the Laos Dabear version of Axitinib, with its relatively accessible cost and st···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 142
As a key targeted drug for advanced renal cell carcinoma, the Laos Big Bear version of Axitinib provides a new treatment option for patients with meta···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 149
The Laos Dabear version of Avatrombopag, as a generic drug option in emerging markets, provides a more accessible treatment choice for patients who ne···【Read More】
Update: 2026-06-01Source: Haiou HealthViews: 122
Selpercatinib is a highly selective RET kinase inhibitor used to treat various solid tumors, including non-small cell lung cancer and medullary thyroi···【Read More】
Update: 2026-05-29Source: Haiou HealthViews: 140
Selpercatinib is a highly selective RET kinase inhibitor used for the treatment of various cancers (such as non-small cell lung cancer, medullary thyr···【Read More】
Update: 2026-05-29Source: Haiou HealthViews: 121
On May 8, 2020, the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib), an oral RET inhibitor developed by Eli Lilly's subsi···【Read More】
Update: 2026-05-29Source: Haiou HealthViews: 130
Ixazomib was approved by the U.S. Food and Drug Administration (FDA) on November 20, 2015, for the treatment of adult patients with relapsed or refrac···【Read More】
Update: 2026-05-28Source: Haiou HealthViews: 162
Ixazomib is an oral proteasome preparation. Platelet counts should be monitored at least monthly during treatment, with increased monitoring frequency···【Read More】
Update: 2026-05-28Source: Haiou HealthViews: 147
Ixazomib is an oral proteasome preparation. When used in combination with lenalidomide and dexamethasone, it can cause side effects such as diarrhea, ···【Read More】
Update: 2026-05-28Source: Haiou HealthViews: 150
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos